Sovaldi Stunner: $2.27 Billion In Sales In Its First Full Quarter
Executive Summary
Sweeping sales of Gilead’s hepatitis C drug could draw more ire from payers, but Gilead is highlighting the cost of non-treatment to address concerns about the drug’s $1,000-a-day price tag. In the U.S., Sovaldi use has been split fairly evenly between private-sector and government payers, firm says.